Plant Name: Dalbergia louvelii
Taxonomic Information:
Plant ID: NPO24287
Plant Latin Name: Dalbergia louvelii
Taxonomy Genus: Dalbergia
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.665E-10 | 3.625E-06 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.831E-09 | 1.993E-05 | CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 4.971E-08 | 3.608E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.292E-07 | 5.626E-04 | AKR1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.178E-07 | 5.626E-04 | CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.216E-07 | 1.000E-03 | CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.985E-06 | 3.602E-03 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.410E-06 | 3.831E-03 | CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.815E-06 | 3.831E-03 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.534E-06 | 4.276E-03 | CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.510E-06 | 5.999E-03 | CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 7.279E-06 | 7.205E-03 | CYP2C19, CYP2C9 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.005E-03 | 3.175E-01 | CYP2C19, CYP2C9, CYP3A4 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.732E-03 | 4.639E-01 | CYP2C19, CYP2C9, CYP3A4, LMNA |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.723E-02 | 1.000E+00 | AKR1B1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.736E-08 | 5.198E-07 | CYP2C9, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.911E-07 | 3.715E-06 | CYP2C9, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.604E-07 | 4.182E-06 | CYP2C9, CYP3A4, CYP2C19 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 6.969E-05 | 3.273E-04 | CYP2C9, AKR1B1, CYP2C19, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 9.399E-05 | 3.273E-04 | CYP2C9, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.034E-04 | 3.273E-04 | CYP2C9, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.305E-04 | 3.541E-04 | CYP2C9, CYP3A4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.074E-04 | 7.301E-04 | CYP2C9, CYP2C19 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 7.478E-03 | 1.515E-02 | AKR1B1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 7.975E-03 | 1.515E-02 | AKR1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
